Background
Methods/design
Study objectives, hypothesis, and design
Study population and eligibility
Inclusion criteria | |
Aged between 18 and 80 years | |
Reflux in the great saphenous vein of > 0.5 s | |
Diameter of the saphenous vein between 2 and 20 mm (standing position) | |
One or more of the symptoms related to the incompetent saphenous vein | |
CEAP classification of C2 through C5 | |
Exclusion criteria | |
Previous treatment in the targeted vein segment | |
Tortuous vein in which the delivery catheter cannot be inserted | |
Aneurysm of target-vein segment of > 20 mm | |
Daily use of narcotic or pain medications to control pain associated with reflux | |
Known hypercoagulable disorder | |
Active malignancy | |
Regular or current use of systemic anticoagulation | |
Previous deep vein thrombosis/pulmonary embolism or active acute superficial thrombophlebitis | |
Unable to comply with the schedule and protocol evaluations | |
Unable to ambulate | |
Unable to provide informed consent | |
Currently pregnant or breastfeeding | |
Known sensitivity to cyanoacrylate adhesives | |
Participation in another clinical study that did not reach the primary endpoint within 30 days prior to enrollment |
Intervention and assessment schedule
Study period | ||||||||
---|---|---|---|---|---|---|---|---|
Screening | Procedure | 3 days | 1 month | 3 months | 6 months | 12 months | 24 months | |
Outpatient visit | √ | √ | √ | √ | √ | √ | √ | |
Physical examination | √ | √ | √ | √ | √ | √ | √ | |
Duplex examination | √ | √ | √ | √ | √ | |||
Inclusion criteria | √ | |||||||
Randomization | √ | |||||||
VCSS | √ | √ | √ | √ | √ | √ | ||
Quality of life score – AVVQ | √ | √ | √ | √ | √ | √ | ||
VAS pain score | √ | √ | √ | |||||
Ecchymosis | √ | √ | ||||||
Other adverse events | √ | √ | √ | √ | √ | √ | √ |